Interleukin Inhibitors in Brief

Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.

Related Videos
Natalie McCormick, PhD | Credit: American College of Rheumatology
Brian LaMoreaux, MD | Credit: Horizon Therapeutics
Related Content
© 2023 MJH Life Sciences

All rights reserved.